US2020323816A1PendingUtilityA1
Kaempferol analog-containing composition
Est. expiryAug 30, 2037(~11.1 yrs left)· nominal 20-yr term from priority
A61K 31/352A23V 2250/2116A61K 2300/00A61K 2121/00A23L 29/30A61P 27/02A61P 9/02A23V 2002/00A23V 2200/31A61P 21/00A23L 33/11A61P 3/00A61K 31/7048A61P 43/00A23V 2200/316A61K 36/21A61K 31/353A23L 29/035
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application provides a composition for improvement in physical activity efficiency, a composition for reducing fatigue, and a composition for improving dynamic/kinetic visual acuity, comprising a kaempferol analog.
Claims
exact text as granted — not AI-modified1 . A composition for improvement in physical activity efficiency, comprising a kaempferol analog of Formula I:
or a glycoside thereof, wherein:
R 1 is —OH, or —OCH 3 ;
R 2 is H, or —OH;
R 3 is H, —OH, or —OCH 3 ;
R 4 is —OH, or —OCH 3 ;
R 5 is H, or —OH; and
R 6 is H, —OH, or —OCH 3 ;
excluding the following compound:
2 . The composition according to claim 1 , wherein the improvement in physical activity efficiency is improvement in endurance.
3 . The composition according to claim 1 , wherein the improvement in physical activity efficiency is reduction of breathlessness.
4 . A composition for reducing fatigue, comprising a kaempferol analog of Formula I:
or a glycoside thereof, wherein:
R 1 is —OH, or —OCH 3 ;
R 2 is H, or —OH;
R 3 is H, —OH, or —OCH 3 ;
R 4 is —OH, or —OCH 3 ;
R 5 is H, or —OH; and
R 6 is H, —OH, or —OCH 3 ;
excluding the following compound:
5 . A composition for improving dynamic/kinetic visual acuity, comprising a kaempferol analog of Formula I:
or a glycoside thereof, wherein:
R 1 is —OH, or —OCH 3 ;
R 2 is H, or —OH;
R 3 is H, —OH, or —OCH 3 ;
R 4 is —OH, or —OCH 3 ;
R 5 is H, or —OH; and
R 6 is H, —OH, or —OCH 3 ;
excluding the following compound:
6 . The composition according to claim 1 , wherein the glycoside of kaempferol analog is represented by Formula I, wherein:
at least one selected from R 1 , R 2 , R 4 , and R 6 is independently selected from —OR 7 , —OR 7 R 8 , and —OR 7 R 8 R 9 ; R 7 is a glucose residue; and R 8 and R 9 are independently selected from a glucose residue, a mannose residue, a galactose residue, a fucose residue, a rhamnose residue, an arabinose residue, a xylose residue, a fructose residue, a glucuronic acid residue, and an apiose residue.
7 . The composition according to claim 1 , wherein the kaempferol analog or a glycoside thereof is selected from the group consisting of the following:
and a glycoside thereof.
8 . The composition according to claim 1 , wherein the kaempferol analog or a glycoside thereof is kaempferol or kaempferol 3-O-glucoside.
9 . The composition according to claim 1 , comprising 0.1 to 200 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof.
10 . The composition according to claim 1 , comprising 0.5 mg to 100 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof.
11 . The composition according to claim 1 , wherein said composition is for administration at a dose of 0.1 mg to 200 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof per administration.
12 . The composition according to claim 1 , wherein said composition is for administration at a dose of 0.5 mg to 100 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof per administration.
13 . The composition according to claim 1 , wherein said composition is for administration at a dose of 0.1 mg to 600 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof per day.
14 . The composition according to claim 1 , wherein said composition is for administration at a dose of 0.5 mg to 200 mg (kaempferol analog equivalent value) of the kaempferol analog or a glycoside thereof per day.
15 . The composition of claim 1 , wherein said composition is for administration to a subject who is hypoxic.
16 . The composition according to claim 1 , wherein said composition is a food and drink.
17 . The composition according to claim 1 , wherein said composition is a pharmaceutical composition.Join the waitlist — get patent alerts
Track US2020323816A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.